EU regulator to review Mylan-Biocon's cancer drug; shares hit new high
Biocon informed that EMA has accepted for review of Mylan's market authorization application (MAA) for a proposed biosimilar Trastuzumab, which is used to treat certain breast and gastric cancer.
Both the companies anticipate that this might become the first MAA for Trastuzumab biosimilar accepted by the EMA for review. Photo: Official Website